アブストラクト
| Title | 膵癌化学療法の最前線 - がん遺伝子異常とプレシジョンメディシン - |
|---|---|
| Subtitle | 今月のテーマ (総論) 膵癌化学療法の進歩 |
| Authors | 小林智, 上野誠, 古瀬純司1) |
| Authors (kana) | |
| Organization | 1)神奈川県立がんセンター消化器内科 |
| Journal | 日本消化器病学会雑誌 |
| Volume | 120 |
| Number | 8 |
| Page | 629-638 |
| Year/Month | 2023 / 8 |
| Article | 報告 |
| Publisher | 日本消化器病学会 |
| Abstract | 要旨: 膵癌におけるプレシジョンメディシンとして, 生殖細胞系列BRCA遺伝子異常を有する患者に対するオラパリブが既に実装されているが, 治療標的となる遺伝子異常はいまだ少ない. 現在, 遺伝子相同組み換え修復に関わる遺伝子異常や, 膵癌患者の90%以上に認められるKRAS遺伝子変異, KRAS遺伝子に変異がない場合に認められることがある融合遺伝子を有する患者に対する分子標的治療薬の開発などが進んでいる. 治療標的となる遺伝子異常を検出するための, 組織または血液検体を用いたがんゲノムプロファイリング検査は既に臨床導入され, 使い分けられる. がんゲノムプロファイリング検査自体の開発も進んでおり, 膵癌化学療法の進歩が期待される. |
| Practice | 臨床医学：内科系 |
| Keywords | プレシジョンメディシン, BRCA遺伝子, 相同組み換え修復, KRAS遺伝子, 血液循環腫瘍DNA |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Reiss KA, Mick R, O'Hara MH, et al : Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. J Clin Oncol 39 ; 2497-2505 : 2021
- 2) Canon J, Rex K, Saiki AY, et al : The clinical KRAS(G12C) inhibitor AMG510 drives anti-tumour immunity. Nature 575 ; 217-223 : 2019
- 3) Hong DS, Fakih MG, Strickler JH, et al : KRAS(G12C) Inhibition with Sotorasib in Ad-vanced Solid Tumors. N Engl J Med 383 ; 1207-1217 : 2020
- 4) Fakih MG, Kopetz S, Kuboki Y, et al : Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation(CodeBreaK100): a pre-specified analysis of a single-arm, phase 2 trial. Lancet Oncol 23 ; 115-124 : 2022
- 5) de Langen AJ, Johnson ML, Mazieres J, et al : So-torasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mu-tation : a randomised, open-label, phase 3 trial. Lancet 401 ; 733-746 : 2023
残りの21件を表示する
- 6) Strickler JH, Satake H, George TJ, et al : Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med 388 ; 33-43 : 2023
- 7) Ou SI, Janne PA, Leal TA, et al : First-in-Human Phase I/IB Dose-Finding Study of Adagrasib(MRTX849) in Patients With Advanced KRAS(G12C) Solid Tumors(KRYSTAL-1). J Clin Oncol 40 ; 2530-2538 : 2022
- 8) Bekaii-Saab TS, Spira AI, Yaeger R, et al : KRYSTAL-1 : Updated activity and safety of adagrasib(MRTX849) in patients(Pts) with unre-sectable or metastatic pancreatic cancer(PDAC) and other gastrointestinal(GI) tumors harboring a KRASG12C mutation. J Clin Oncol 40(suppl); 519 : 2022
- 9) Awad MM, Liu S, Rybkin, II, et al : Acquired Re-sistance to KRAS(G12C) Inhibition in Cancer. N Engl J Med 384 ; 2382-2393 : 2021
- 10) Hofmann MH, Gerlach D, Misale S, et al : Expand-ing the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov 12 ; 924-937 : 2022
- 11) Hallin J, Bowcut V, Calinisan A, et al : Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med 28 ; 2171-2182 : 2022
- 12) Cheng R, Li F, Zhang M, et al : A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers. Cell Res 33 ; 30-45 : 2023
- 13) Tolani B, Celli A, Yao Y, et al : Ras-mutant can-cers are sensitive to small molecule inhibition of V-type ATPases in mice. Nat Biotechnol 40 ; 1834-1844 : 2022
- 14) Gustafson WC, Wildes D, Rice MA, et al : Direct targeting of RAS in pancreatic ductal adenocarci-noma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor. J Clin Oncol 40(suppl); 591 : 2022
- 15) Hofmann MH, Gmachl M, Ramharter J, et al : BI-3406, a Potent and Selective SOSI-KRAS Interac-tion Inhibitor, Is Effective in KRAS-Driven Can-cers through Combined MEK Inhibition. Cancer Discov 11 ; 142-157 : 2021
- 16) Zhou C,Fan Z, Zhou Z, et al : Discovery of the First-in-Class Agonist-Based SOSI PROTACs Ef-fective in Human Cancer Cells Harboring Various KRAS Mutations. J Med Chem 65 ; 3923-3942 : 2022
- 17) Neel BG, Gu H, Pao L : The 'Shp'ing news : SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28 ; 284-293 : 2003
- 18) Brana I, Shapiro G, Johnson ML, et al : Initial re-sults from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tu-mors. J Clin Oncol 39(suppl); 3005 : 2021
- 19) Koczywas M, Haura E, Janne PA, et al : Anti-tumor activity and tolerability of the SHP2 inhibi-tor RMC-4630 as a single agent in patients with RAS-addicted solid cancers. Cancer Res 81(suppl); LB001 : 2021
- 20) Jonna S, Feldman RA, Swensen J, et al : Detection of NRG1 Gene Fusions in Solid Tumors. Clin Can-cer Res 25 ; 4966-4972 : 2019
- 21) Philip PA, Azar I, Xiu J, et al : Molecular Charac-terization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Clin Cancer Res 28 ; 2704-2714 : 2022
- 22) Ghosh T, Greipp PT, Knutson D, et al : BRAF Re-arrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation. Arch Pathol Lab Med 146 ; 840-845 : 2022
- 23) Umemoto K, Sunakawa Y : The potential tar-geted drugs for fusion genes including NRG1 in pancreatic cancer. Crit Rev Oncol Hematol 166 ; 103465 : 2021
- 24) Nakamura Y, Taniguchi H, Ikeda M, et al : Clini-cal utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer : SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26 ; 1859-1864 : 2020
- 25) Umemoto K, Sunakawa Y, Ueno M, et al : Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Br J Cancer 128 ; 1603-1608 : 2023
- 26) Pishvaian MJ, Blais EM, Brody JR, et al : Overall survival in patients with pancreatic cancer re-ceiving matched therapies following molecular profiling : a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 21 ; 508-518 : 2020
